Company performance
Current Price
as of Jan 23, 2025$0.99
P/E Ratio
N/A
Market Cap
$89.41M
Description
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerIMUX
- Price$0.9926+0.92%
Trading Information
- Market cap$89.41M
- Float96.98%
- Average Daily Volume (1m)1,237,881
- Average Daily Volume (3m)980,169
- EPS-$1.24
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$24.37M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$25.68M
- EV$108.93M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B2.17
Documents
SEC Filings
Earnings Calls
Factset Street Account